May 28, 2020
Hikma launches Dicyclomine Hydrochloride Oral Solution
Nov 21, 2019
FDA approves new treatment for adults with partial-onset seizures
Jun 25, 2019
Eisai Presents Data To Assess Seizure Freedom With FYCOMPA® Monotherapy In Newly Diagnosed Or Untreated Patients With Partial Onset Seizures
Jun 13, 2019
Eisai To Present FYCOMPA® Seizure FREEDOM Data In New Onset Patients And Pediatric Data At The 33rd International Epilepsy Congress
May 23, 2019
Pain Therapeutics Report, 2018-2019 & 2028 - Latest Concepts of Pathomechanisms of Pain as a Basis for Management and Development of New Pharmacotherapies
May 09, 2019
Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII
Apr 30, 2019
Cannabis-based Medicine May Reduce Seizures for Children with Difficult-to-Treat Epilepsy
Dec 04, 2018
New Analyses Evaluate Long-Term Convulsive Seizure Freedom Rates With Use Of Adjunctive FYCOMPA® (perampanel) CIII In Adult Patients Presented at Annual Meeting of the American Epilepsy Society (AES)
Nov 30, 2018
UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership
Nov 21, 2018
Eisai To Present FYCOMPA Long-Term Sustained Seizure Freedom And Pediatric Data At Upcoming American Epilepsy Society Annual Meeting
Aug 13, 2018
Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection
Jul 17, 2018
Neurana Pharmaceuticals Appoints Craig Thompson as President and CEO
Jun 13, 2018
Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS®)
Apr 20, 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
Apr 19, 2018
Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA
Mar 30, 2018
Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA® (perampanel) Pediatric Indications
Mar 01, 2018
WG Critical Care (WGCC), A Pharmasphere Company, Launches The First And Only Generic Ready-To-Use Esmolol Hydrochloride In Water For Injection
Nov 22, 2017
Eisai Announces Presentations on Perampanel (marketed as FYCOMPA CIII) at the Annual Meeting of the American Epilepsy Society (AES)
Nov 06, 2017
UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
Oct 19, 2017
Nexus Pharmaceuticals Receives FDA Approval for Procainamide HCL Injection, USP